Compare Aspen Aerogels Inc (ASPN) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aspen Aerogels Inc vs Danaher Corporation — how do they compare? Aspen Aerogels Inc trades at $5.15 (market cap $427.65M), while Danaher Corporation trades at $199.77 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 329.4× Aspen Aerogels Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ASPN | DHR | |
|---|---|---|
Market Cap | $427.65M | $140.88B |
Sector | Technology | Health |
52-Week High | $8.82 | $242.05 |
52-Week Low | $2.57 | $161.91 |
Enterprise Value | $382.60M | $153.66B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
Danaher (DHR) trades at $199.05, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest and profit margins have compressed from pandemic peaks. Recent business developments include the shareholder approval of the Masimo acquisition and new product launches in its SCIEX division, suggesting ongoing strategic investment.
The outlook is cautiously optimistic, supported by a dominant 'Buy' analyst consensus and a price target implying ~7% upside. Key opportunities lie in the firm's biotechnology segment strength and strategic M&A. Risks include ongoing margin pressure, integration challenges from acquisitions, and a relatively high valuation (P/E of 38.6) that demands sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
